Company / Operating Cash Flow per Share
Gain Therapeutics, Inc. Operating Cash Flow per Share History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.16
FY2024
5-year range
-$1.24 / -$0.91
FY2021-FY2024
Trend
+5.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow per Share returned to growth in FY2024 after 2 years of decline, reaching $-1.16.
Based on SEC 10-K filings.
-1.16 in FY2024.
Declined from $-1.04 to $-1.16 over the past 2 years.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating cash flow per share increased 5.8% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$1.16 | +5.8% |
| FY2023 | -$1.24 | -18.8% |
| FY2022 | -$1.04 | -13.8% |
| FY2021 | -$0.91 | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026